NCT05756179RecruitingPhase 3
Effect of Diosmin and Hesperidin in Treatment of Patients With Rheumatoid Arthritis
Clinical Study Evaluating the Effect of Diosmin and Hesperidin in Treatment of Patients With Rheumatoid Arthritis
Source: ClinicalTrials.gov · Last updated 25 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Evaluating the effect of the flavonoids combination (diosmin and hesperidin) as adjuvant therapy on patients with rheumatoid arthritis
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 21 Feb 2023
- Start date
- 18 Jul 2023
- Primary completion date
- Sept 2025
- Lead sponsor
- Alexandria University
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT05756179
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 80
- From 18 Jul 2023 to the primary completion date, Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with liver, renal impairment or any other inflammatory diseases.
Other
- Pregnant and lactating females.
- Patients on TNF-α (tumor necrosis factor- α) or IL-1β (interleukin-1β) antagonists.
Who the study is looking for
- Patients with mild to moderate disease activity.
- Patient age must be more than 18 years.
Age in the registry: 19 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Alexandria University Hospital Coordinator of this site? Confirm its status | Alexandria | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.